Company intelligence / Profile preview

BioAscent

Newhouse, Scotland, United Kingdombioascent.com ↗

Ownership: Private
Employees: ~51
Development stage: Other

Overview

BioAscent does not develop its own drugs but has supported >150 assays and >30 hit-to-lead campaigns for clients since its founding in early-stage drug discovery. Their expertise spans all major biological target classes and therapeutic areas. They have successfully driven projects to candidate selection and outlicensing to big pharma partners.

Modalities: Small moleculePeptidesBiologicFragment-based drug discovery
Industry: Drug Discovery Services

Partnerships

Medical Research Scotland – PhD program partnership with University of Glasgow Advanced Research Centre focusing on GPCR research/type II diabetes treatment

Beyond the preview

Go deeper on BioAscent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioAscent.

Explore the full profile